X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Unichem Lab with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

UNICHEM LAB vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    UNICHEM LAB CIPLA UNICHEM LAB/
CIPLA
 
P/E (TTM) x 21.8 43.6 50.1% View Chart
P/BV x 2.3 3.6 64.0% View Chart
Dividend Yield % 0.8 0.4 231.1%  

Financials

 UNICHEM LAB   CIPLA
EQUITY SHARE DATA
    UNICHEM LAB
Mar-16
CIPLA
Mar-17
UNICHEM LAB/
CIPLA
5-Yr Chart
Click to enlarge
High Rs334622 53.7%   
Low Rs174458 38.0%   
Sales per share (Unadj.) Rs146.9181.9 80.8%  
Earnings per share (Unadj.) Rs11.912.9 92.4%  
Cash flow per share (Unadj.) Rs16.229.3 55.2%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.80.4 212.6%  
Book value per share (Unadj.) Rs105.1155.7 67.5%  
Shares outstanding (eoy) m90.84804.51 11.3%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x1.73.0 58.2%   
Avg P/E ratio x21.442.0 50.9%  
P/CF ratio (eoy) x15.718.4 85.2%  
Price / Book Value ratio x2.43.5 69.7%  
Dividend payout %16.815.5 108.2%   
Avg Mkt Cap Rs m23,073434,516 5.3%   
No. of employees `0005.723.0 24.6%   
Total wages/salary Rs m2,55826,338 9.7%   
Avg. sales/employee Rs Th2,352.56,349.1 37.1%   
Avg. wages/employee Rs Th450.91,143.0 39.4%   
Avg. net profit/employee Rs Th190.4449.3 42.4%   
INCOME DATA
Net Sales Rs m13,346146,302 9.1%  
Other income Rs m1922,287 8.4%   
Total revenues Rs m13,538148,589 9.1%   
Gross profit Rs m1,63924,758 6.6%  
Depreciation Rs m39013,229 2.9%   
Interest Rs m291,594 1.8%   
Profit before tax Rs m1,41212,222 11.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m-4-70 5.3%   
Extraordinary Inc (Exp) Rs m-350-   
Tax Rs m2931,798 16.3%   
Profit after tax Rs m1,08010,354 10.4%  
Gross profit margin %12.316.9 72.6%  
Effective tax rate %20.714.7 140.9%   
Net profit margin %8.17.1 114.4%  
BALANCE SHEET DATA
Current assets Rs m5,97987,370 6.8%   
Current liabilities Rs m2,43233,081 7.4%   
Net working cap to sales %26.637.1 71.6%  
Current ratio x2.52.6 93.1%  
Inventory Days Days6387 72.5%  
Debtors Days Days6062 96.9%  
Net fixed assets Rs m6,403111,567 5.7%   
Share capital Rs m1821,609 11.3%   
"Free" reserves Rs m9,293123,645 7.5%   
Net worth Rs m9,548125,254 7.6%   
Long term debt Rs m23036,454 0.6%   
Total assets Rs m12,843209,532 6.1%  
Interest coverage x50.08.7 577.2%   
Debt to equity ratio x00.3 8.3%  
Sales to assets ratio x1.00.7 148.8%   
Return on assets %8.65.7 151.5%  
Return on equity %11.38.3 136.9%  
Return on capital %14.38.5 168.7%  
Exports to sales %29.234.2 85.4%   
Imports to sales %6.38.3 76.1%   
Exports (fob) Rs m3,90050,050 7.8%   
Imports (cif) Rs m84712,203 6.9%   
Fx inflow Rs m4,35651,066 8.5%   
Fx outflow Rs m1,16217,678 6.6%   
Net fx Rs m3,19433,388 9.6%   
CASH FLOW
From Operations Rs m1,11923,824 4.7%  
From Investments Rs m-853-13,127 6.5%  
From Financial Activity Rs m-334-13,239 2.5%  
Net Cashflow Rs m-68-2,478 2.8%  

Share Holding

Indian Promoters % 50.1 16.0 313.1%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 15.1 12.2 123.8%  
FIIs % 3.0 23.7 12.7%  
ADR/GDR % 0.0 1.1 -  
Free float % 31.7 26.2 121.0%  
Shareholders   20,176 161,166 12.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare UNICHEM LAB With:   ALEMBIC PHARMA  STRIDES SHASUN LTD  FDC LTD.  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare UNICHEM LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Bank & Realty Stocks Rally(Closing)

Indian share markets surged further in the afternoon session and finished in the green for the second straight session on heavy buying in realty stocks, metal stocks and bank stocks.

Related Views on News

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

Sep 19, 2016

Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

UNICHEM LAB SHARE PRICE


Aug 23, 2017 (Close)

TRACK UNICHEM LAB

  • Track your investment in UNICHEM LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

UNICHEM LAB 5-YR ANALYSIS

COMPARE UNICHEM LAB WITH

MARKET STATS